Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRX-101 vs Lurasidone for Bipolar Depression with Subacute Suicidal Ideation
NCT03395392Phase 3Completed
- Sponsor
- NRx Pharmaceuticals
- Start
- May 2022
- Primary completion
- Feb 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of d-cycloserine + lurasidone in bipolar disorder (BD), suicidal ideation, sponsored by NRx Pharmaceuticals. Started May 2022; status: completed.
02
Drugs
d-cycloserine + lurasidone
03
Conditions
bipolar disorder (BD)suicidal ideation
Beyond the preview
Go deeper on NCT03395392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03395392.